Dr. Julie Holland on How MDMA Works as a Catalyst for Psychotherapy
MDMA acts as a serotonin agonist, meaning it releases a wave of serotonin across the brain. That flood produces a feeling of happiness and ease. One of serotonin's jobs is signaling satiety, that sense of being full, of already having what you need and not reaching for anything more. So when someone takes MDMA, they get the push of a stimulant alongside a heavy serotonin component. The result is a person who is calm and comfortable, who doesn't feel any particular lack, and who at the same time wants to pay attention, keep talking, and stay connected.
The other major piece is oxytocin, which MDMA appears to raise as well. Oxytocin is the hormone tied to bonding, trust, and feeling close to another person. A mother nursing her infant runs high on it, and so much of the bonding between them traces back to that. There's a surge of it after orgasm too, which helps couples attach. Because MDMA lifts both serotonin and oxytocin, the closeness it encourages can land right where it matters in a treatment setting: between the client and the therapist.
Research into what separates effective therapy from ineffective therapy keeps pointing to one factor above most others, the therapeutic alliance. That's a measure of how connected a patient feels to their therapist, whether they sense the two of them are on the same side, allied in the same struggle. With serotonin and oxytocin both elevated, a patient tends to feel genuine warmth toward the therapist, and that warmth can move the outcome in a better direction.
There's a third element, rooted in the stimulant side of the drug. Feeling happy, relaxed, and physically fortified, a person also feels more confident, more capable of going into the territory where they were hurt, the places tied to their trauma. Someone with post-traumatic stress disorder has to process that trauma. They have to dig down and bring up the thing they've been defending against and keeping hidden, look at it directly, and ideally arrive at some measure of acceptance for what happened to them.
By that logic MDMA is almost purpose-built to assist this kind of work. It would be hard to design a drug better suited to letting therapy reach deeper, move quicker, and do more with less wasted time. Good therapy ordinarily runs for months, often years, and a large part of that is spent with patients braced and reluctant to touch the exact material they most need to touch, because it hurts to touch it.
Think of it along the lines of anesthesia during surgery. With the pain dialed down and the patient feeling strong enough to reach the spot where the damage sits, real therapeutic work can finally get done.